Q-omics provides the consensus-scored NUP188 profile across patient tissues and cancer cell-line models. NUP188 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NUP188 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, NUP188 protein abundance shows 31,618 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where NUP188 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP188 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP188 survival associations across molecular data types. NUP188 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP188 RNA expression–survival associations across cancer types. High NUP188 expression shows unfavorable associations in MESO, ACC, BLCA, LIHC and LGG, but favorable associations in UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NUP188 RNA expression.
This table summarizes NUP188 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NUP188. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP188 shows higher tumor expression in COAD, HNSC, STAD, LIHC, BRCA and READ. The COAD box plot shows higher NUP188 RNA expression in tumor versus normal tissue (log2 FC = +1.291, t-test p < 0.001).
This table shows molecular features associated with NUP188 in patient tissues and cancer cell lines. In patient samples, NUP188 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP188 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
